HRP20100160T1 - Pripravak koji sadrži roziglitazon i metformin - Google Patents

Pripravak koji sadrži roziglitazon i metformin Download PDF

Info

Publication number: HRP20100160T1
Authority: HR; Croatia
Prior art keywords: dosage form; oral dosage; form according; core; coating
Prior art date: 2003-08-11

Application number

HR20100160T

Other languages

English (en)

Croatian (hr)

Inventor

John Coles Peter

Colin Mackenzie Donald

Norman Jr. Mudd Paul

Original Assignee

Smithkline Beecham (Cork) Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-11

Filing date

2010-03-18

Publication date

2010-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100160(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-18 Application filed by Smithkline Beecham (Cork) Limited filed Critical Smithkline Beecham (Cork) Limited

2010-05-31 Publication of HRP20100160T1 publication Critical patent/HRP20100160T1/hr

Links

YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title claims abstract 11
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract 10
229960003105 metformin Drugs 0.000 title claims abstract 10
229960004586 rosiglitazone Drugs 0.000 title 1
239000006186 oral dosage form Substances 0.000 claims abstract 23
239000011248 coating agent Substances 0.000 claims abstract 17
238000000576 coating method Methods 0.000 claims abstract 17
150000003839 salts Chemical class 0.000 claims abstract 13
239000012453 solvate Substances 0.000 claims abstract 12
239000000463 material Substances 0.000 claims 4
229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 claims 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 2
239000002702 enteric coating Substances 0.000 claims 2
238000009505 enteric coating Methods 0.000 claims 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
238000000034 method Methods 0.000 claims 2
229920000642 polymer Polymers 0.000 claims 2
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
229920001800 Shellac Polymers 0.000 claims 1
229920001577 copolymer Polymers 0.000 claims 1
230000003628 erosive effect Effects 0.000 claims 1
239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
150000002688 maleic acid derivatives Chemical class 0.000 claims 1
229920000193 polymethacrylate Polymers 0.000 claims 1
229940113147 shellac Drugs 0.000 claims 1
239000004208 shellac Substances 0.000 claims 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
235000013874 shellac Nutrition 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HR20100160T 2003-08-11 2010-03-18 Pripravak koji sadrži roziglitazon i metformin HRP20100160T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0318824.0A GB0318824D0 (en)	2003-08-11	2003-08-11	Novel composition
PCT/EP2004/008970 WO2005013956A1 (en)	2003-08-11	2004-08-09	Novel composition comprising rosiglitazone and another antidiabetic agent

Publications (1)

Publication Number	Publication Date
HRP20100160T1 true HRP20100160T1 (hr)	2010-05-31

Family

ID=27840010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100160T HRP20100160T1 (hr)	2003-08-11	2010-03-18	Pripravak koji sadrži roziglitazon i metformin

Country Status (37)

Country	Link
US (1)	US20080206336A1 (es)
EP (1)	EP1663191B1 (es)
JP (1)	JP4714147B2 (es)
KR (1)	KR20060071396A (es)
CN (2)	CN1835741B (es)
AP (1)	AP2006003489A0 (es)
AR (1)	AR045230A1 (es)
AT (1)	ATE455542T1 (es)
AU (1)	AU2004262933B2 (es)
BR (1)	BRPI0413419A (es)
CA (1)	CA2534480A1 (es)
CY (1)	CY1109923T1 (es)
DE (1)	DE602004025257D1 (es)
DK (1)	DK1663191T3 (es)
EA (2)	EA200800966A1 (es)
EC (1)	ECSP066338A (es)
ES (1)	ES2339554T3 (es)
GB (1)	GB0318824D0 (es)
HK (1)	HK1092051A1 (es)
HR (1)	HRP20100160T1 (es)
IL (1)	IL173177A0 (es)
IS (1)	IS2745B (es)
MA (1)	MA27996A1 (es)
MX (1)	MXPA06001629A (es)
MY (1)	MY151053A (es)
NO (1)	NO20061161L (es)
NZ (1)	NZ544632A (es)
OA (1)	OA13233A (es)
PE (1)	PE20050357A1 (es)
PL (1)	PL1663191T3 (es)
PT (1)	PT1663191E (es)
SG (1)	SG165178A1 (es)
SI (1)	SI1663191T1 (es)
TW (1)	TW200517146A (es)
UA (1)	UA82537C2 (es)
UY (1)	UY28461A1 (es)
WO (1)	WO2005013956A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR030920A1 (es) *	1999-11-16	2003-09-03	Smithkline Beecham Plc	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
GB0203296D0 (en) *	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
US8637512B2 (en) *	2002-07-29	2014-01-28	Glaxo Group Limited	Formulations and method of treatment
US20050169994A1 (en) *	2003-11-25	2005-08-04	Burke Matthew D.	Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
KR20110052641A (ko) *	2008-07-18	2011-05-18	베일언트 파마슈티컬스 인터내셔널	변형 방출형 제형 및 이의 이용 방법
US20100323016A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
US20100323015A1 (en) *	2008-07-18	2010-12-23	Biljana Nadjsombati	Modified release formulation and methods of use
WO2011161521A1 (en) *	2010-06-21	2011-12-29	Lupin Limited	Compositions comprising metformin and rosiglitazone
MX342120B (es) *	2010-07-09	2016-09-14	William Owen Wilkison	Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.
CN102727459A (zh) *	2011-04-15	2012-10-17	江苏豪森医药集团有限公司	一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) *	1988-08-26	1988-09-28	Staniforth J N	Controlled release tablet
US5952509A (en) *	1996-06-27	1999-09-14	Takeda Chemical Industries, Ltd.	Production of benzaldehyde compounds
GB9619757D0 (en) *	1996-09-21	1996-11-06	Knoll Ag	Chemical process
US20010049380A1 (en) *	1997-06-18	2001-12-06	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) *	1997-06-18	2002-01-10	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) *	1997-10-13	2002-01-17	Smithkline Beecham P.L.C.	Use of thiazolidinediones for the treatment of hyperglycaemia
ATE267589T1 (de) *	1998-04-03	2004-06-15	Egalet As	Zusammensetzung mit kontrollierter wirkstoff- freisetzung
US6099862A (en) *	1998-08-31	2000-08-08	Andrx Corporation	Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) *	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
DE69833179T2 (de) *	1998-11-10	2006-09-07	The Procter & Gamble Company, Cincinnati	Bleichmittelzusammensetzungen
US20040102486A1 (en) *	1998-11-12	2004-05-27	Smithkline Beecham Corporation	Novel method of treatment
US20030153607A1 (en) *	1998-11-12	2003-08-14	Smithkline Beecham P.L.C.	Novel composition and use
NZ511614A (en) *	1998-11-12	2003-12-19	Smithkline Beecham P	Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
US20040081697A1 (en) *	1998-11-12	2004-04-29	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1231917A2 (en) *	1999-11-16	2002-08-21	Smithkline Beecham Plc	Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
AU2001257456B2 (en) *	2000-05-01	2006-02-09	Aeropharm Technology, Inc.	A core formulation
GB0027471D0 (en) *	2000-11-08	2000-12-27	Smithkline Beecham Plc	Processes
GB0120835D0 (en) *	2001-08-28	2001-10-17	Smithkline Beecham Plc	Process
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
GB0203296D0 (en) *	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
MY139719A (en) *	2002-02-12	2009-10-30	Glaxo Group Ltd	Oral dosage form for controlled drug release
US7785627B2 (en) *	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

2003
- 2003-08-11 GB GBGB0318824.0A patent/GB0318824D0/en not_active Ceased
2004
- 2004-08-09 US US10/567,803 patent/US20080206336A1/en not_active Abandoned
- 2004-08-09 SI SI200431376T patent/SI1663191T1/sl unknown
- 2004-08-09 WO PCT/EP2004/008970 patent/WO2005013956A1/en active Application Filing
- 2004-08-09 MX MXPA06001629A patent/MXPA06001629A/es active IP Right Grant
- 2004-08-09 CA CA002534480A patent/CA2534480A1/en not_active Abandoned
- 2004-08-09 DE DE602004025257T patent/DE602004025257D1/de active Active
- 2004-08-09 SG SG200901679-1A patent/SG165178A1/en unknown
- 2004-08-09 PE PE2004000771A patent/PE20050357A1/es not_active Application Discontinuation
- 2004-08-09 CN CN2004800232304A patent/CN1835741B/zh not_active Expired - Fee Related
- 2004-08-09 DK DK04741403.2T patent/DK1663191T3/da active
- 2004-08-09 AP AP2006003489A patent/AP2006003489A0/xx unknown
- 2004-08-09 OA OA1200600045A patent/OA13233A/en unknown
- 2004-08-09 EA EA200800966A patent/EA200800966A1/ru unknown
- 2004-08-09 PT PT04741403T patent/PT1663191E/pt unknown
- 2004-08-09 BR BRPI0413419-2A patent/BRPI0413419A/pt not_active IP Right Cessation
- 2004-08-09 NZ NZ544632A patent/NZ544632A/en not_active IP Right Cessation
- 2004-08-09 MY MYPI20043234 patent/MY151053A/en unknown
- 2004-08-09 ES ES04741403T patent/ES2339554T3/es active Active
- 2004-08-09 AT AT04741403T patent/ATE455542T1/de active
- 2004-08-09 EP EP04741403A patent/EP1663191B1/en active Active
- 2004-08-09 AR ARP040102846A patent/AR045230A1/es not_active Application Discontinuation
- 2004-08-09 TW TW093123804A patent/TW200517146A/zh unknown
- 2004-08-09 UY UY28461A patent/UY28461A1/es not_active Application Discontinuation
- 2004-08-09 EA EA200600400A patent/EA011550B1/ru not_active IP Right Cessation
- 2004-08-09 JP JP2006522974A patent/JP4714147B2/ja not_active Expired - Fee Related
- 2004-08-09 KR KR1020067002884A patent/KR20060071396A/ko not_active Application Discontinuation
- 2004-08-09 AU AU2004262933A patent/AU2004262933B2/en not_active Ceased
- 2004-08-09 PL PL04741403T patent/PL1663191T3/pl unknown
- 2004-08-09 CN CN2011103143770A patent/CN102397551A/zh active Pending
- 2004-09-08 UA UAA200601353A patent/UA82537C2/uk unknown
2006
- 2006-01-16 IL IL173177A patent/IL173177A0/en unknown
- 2006-01-31 EC EC2006006338A patent/ECSP066338A/es unknown
- 2006-02-17 MA MA28817A patent/MA27996A1/fr unknown
- 2006-03-02 IS IS8337A patent/IS2745B/is unknown
- 2006-03-10 NO NO20061161A patent/NO20061161L/no not_active Application Discontinuation
- 2006-11-15 HK HK06112571.6A patent/HK1092051A1/xx not_active IP Right Cessation
2010
- 2010-03-18 HR HR20100160T patent/HRP20100160T1/hr unknown
- 2010-03-22 CY CY20101100261T patent/CY1109923T1/el unknown

Also Published As

Publication number	Publication date
ATE455542T1 (de)	2010-02-15
AU2004262933A1 (en)	2005-02-17
ES2339554T3 (es)	2010-05-21
ECSP066338A (es)	2006-07-28
JP4714147B2 (ja)	2011-06-29
IS2745B (is)	2011-08-15
NO20061161L (no)	2006-03-10
CN1835741B (zh)	2011-12-14
BRPI0413419A (pt)	2006-10-10
AP2006003489A0 (en)	2006-02-28
HK1092051A1 (en)	2007-02-02
JP2007501830A (ja)	2007-02-01
SI1663191T1 (sl)	2010-05-31
EP1663191A1 (en)	2006-06-07
CN1835741A (zh)	2006-09-20
MY151053A (en)	2014-03-31
AR045230A1 (es)	2005-10-19
CN102397551A (zh)	2012-04-04
CA2534480A1 (en)	2005-02-17
UA82537C2 (uk)	2008-04-25
UY28461A1 (es)	2005-03-31
NZ544632A (en)	2009-03-31
CY1109923T1 (el)	2014-09-10
US20080206336A1 (en)	2008-08-28
GB0318824D0 (en)	2003-09-10
MA27996A1 (fr)	2006-07-03
TW200517146A (en)	2005-06-01
IL173177A0 (en)	2006-06-11
KR20060071396A (ko)	2006-06-26
PL1663191T3 (pl)	2010-06-30
EP1663191B1 (en)	2010-01-20
PE20050357A1 (es)	2005-06-01
DK1663191T3 (da)	2010-04-26
EA200800966A1 (ru)	2009-04-28
IS8337A (is)	2006-03-02
WO2005013956A1 (en)	2005-02-17
OA13233A (en)	2006-12-13
EA011550B1 (ru)	2009-04-28
SG165178A1 (en)	2010-10-28
DE602004025257D1 (de)	2010-03-11
AU2004262933B2 (en)	2009-12-10
PT1663191E (pt)	2010-03-16
EA200600400A1 (ru)	2006-08-25
MXPA06001629A (es)	2006-04-28

Publication	Publication Date	Title
HRP20100160T1 (hr)	2010-05-31	Pripravak koji sadrži roziglitazon i metformin
HRP20020416B1 (en)	2011-04-30	Novel composition and use
HRP20010343B1 (en)	2010-11-30	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DZ3316A1 (fr)	2001-09-20	Sels de chlorhydrate de 5- 4- 2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
MY129317A (en)	2007-03-30	Taste masked pharmaceutical compositions
DK1246622T3 (da)	2007-01-29	Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse
ATE268593T1 (de)	2004-06-15	Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
WO2005020929A3 (en)	2005-08-25	Sustained release dosage forms of ziprasidone
EA200701680A1 (ru)	2007-12-28	Лекарственная форма для перорального введения, содержащая розиглитазон
DE60004196D1 (de)	2003-09-04	Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
HRP20010342B1 (en)	2008-04-30	Pharmaceutical composition for modified release insulin sensitiser
CY1105252T1 (el)	2010-03-03	Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης
PE20050335A1 (es)	2005-06-01	Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
AR048948A1 (es)	2006-06-14	Una composicion farmaceutica antimicobacteriana
LU90616B1 (fr)	2007-06-08	Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene
AR038417A1 (es)	2005-01-12	Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral
LU90617B1 (fr)	2001-06-15	Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-Y1)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene
WO2004004684A8 (en)	2004-12-29	Controlled-release pharmaceutical formulations
DK1446404T3 (da)	2006-10-09	Rosiglitazonedisylater og deres anvendelse som antidiabetika
HRP20030068B1 (en)	2008-07-31	Tartrate salt of thiazolidinedione derivative
AP2003002737A0 (en)	2003-03-31	Tartrate salts of thiazolidinedione derivatives
AU6255001A (en)	2001-12-17	5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
AU9202801A (en)	2002-04-08	Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione
SI1265893T1 (sl)	2005-12-31	Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona
AR034103A1 (es)	2004-02-04	Composicion farmaceutica que comprende ligandos de neurofilina para el tratamiento de condiciones oculares